San Francisco, May 16, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it is starting recruiting patients for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Recruitment for this randomized, double-blind, placebo-controlled trial will begin in one of the 29 participating trial centers in the European Union and be expanded rapidly to also include 5 centers in the United States.
The patients being recruited experience a ST-Elevation Myocardial Infarction (STEMI) which is a very serious type of heart attack that results from a complete blockage in a coronary artery. Upon urgent hospitalization, initial treatment is intended to restore blood perfusion to salvage as much of the jeopardized heart muscle as possible. This is typically accomplished through a percutaneous coronary intervention (PCI). However, the area of the heart that is already damaged cannot be restored through procedures or medications that are currently available. In the Phase 2 clinical trial, Recardio will evaluate a novel approach to actually restore lost myocardial function by increasing the regenerative capacity of the heart muscle. Specifically, Filgrastim will be used to induce stem cell mobilization from the bone marrow to circulating blood while Dutogliptin will activate stem cell migration and homing from blood to the site of ischemia or injury in the heart. Once on site, these stem cells and the signaling factors that they express will have the capacity to regenerate tissue.
“Initiation of the recruitment stage of this Phase 2 study marks another important and timely milestone in the development of Recardio’s therapeutic platform with dutogliptin as a regenerative medication for patients with cardiovascular diseases” remarked Roman Schenk, Executive Chairman of Recardio. “We look forward to collaborating with an impressive network of European and North American centers to fully execute the study in the coming months.”
More information about the clinical program is available by visiting the “clinicaltrials.gov” website at the following link.
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is pursuing a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/